Track OSTX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$44.95M
Enterprise Value-$196.79M
Revenue (TTM)-
Net Income (TTM)-$28.75B
Free Cash Flow (TTM)-$14.70M
Financial Health
Cash$269.83M
Net Debt-$241.74M
Debt Ratio4.11
Debt to Equity-4.61
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings0
EV to EBITDA6.93
Price to Book-7.37
Price to Free Cash Flow-3.06
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-43.25%
Return on Assets-688.91%
Return on Equity9807.64%
Return on Total Capital-43.25%
Return on Capital Employed16.98%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue0.00%
Diluted EPS-74.80%
Total Debt-98.37%
Capital Expenditures-25.36%
Free Cash Flow-99.03%
CAGR (3Y)
Revenue0.00%
Diluted EPS-89.94%
Total Debt-99.58%
Capital Expenditures1000.00%
Free Cash Flow-99.96%
CAGR (1Y)
Revenue0.00%
Diluted EPS-99.90%
Total Debt0.00%
Capital Expenditures1000.00%
Free Cash Flow-100.00%
$1.55$0.00|+0.00%
Last updated: Jul 23, 9:34 AM ET
52W High$2.57
52W Low$1.15
50D SMA$1.76
200D SMA$1.63
Volume6.08K
OS Therapies Incorporated
115 Pullman Crossing Road, Grasonville, MD, United States, 21638
IPO
2024
Employees
4
Industry
Biotechnology
Sector
Healthcare
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20251-1
0
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0